Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2009-3-20
pubmed:abstractText
There is growing evidence that a cross-talk exists between the renin-angiotensin (Ang) system and lipoproteins. We investigated the role of high-density lipoprotein (HDL) on Ang II type 1 receptor (AT1R) regulation and subsequent Ang II-mediated signaling under diabetic conditions. To investigate the effect of HDL on AT1R expression in vivo, apolipoprotein A-I gene transfer was performed 5 days after streptozotocin injection. Six weeks after apolipoprotein A-I gene transfer, the 1.9-fold (P=0.001) increase of HDL cholesterol was associated with a 4.7-fold (P<0.05) reduction in diabetes mellitus-induced aortic AT1R expression. Concomitantly, NAD(P)H oxidase activity, Nox 4, and p22(phox) mRNA expression were reduced 2.6-fold, 2.0-fold, and 1.5-fold (P<0.05), respectively, whereas endothelial NO synthase dimerization was increased 3.3-fold (P<0.005). Apolipoprotein A-I transfer improved NO bioavailability as indicated by ameliorated acetylcholine-dependent vasodilation in the streptozotocin-Ad.hapoA-I group compared with streptozotocin-induced diabetes mellitus. In vitro, HDL reduced the hyperglycemia-induced upregulation of the AT1R in human aortic endothelial cells. This was associated with a 1.3-fold and 2.2-fold decreases in reactive oxygen species and NAD(P)H oxidase activity, respectively (P<0.05). Finally, HDL reduced the responsiveness to Ang II, as indicated by decreased oxidative stress in the hyperglycemia+HDL+Ang II group compared with the hyperglycemia+Ang II group. In conclusion, vascular-protective effects of HDL include the downregulation of the AT1R.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1524-4563
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
53
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
682-7
pubmed:meshHeading
pubmed-meshheading:19273745-Angiotensin II, pubmed-meshheading:19273745-Animals, pubmed-meshheading:19273745-Aorta, pubmed-meshheading:19273745-Apolipoprotein A-I, pubmed-meshheading:19273745-Diabetes Mellitus, Experimental, pubmed-meshheading:19273745-Diabetic Angiopathies, pubmed-meshheading:19273745-Dimerization, pubmed-meshheading:19273745-Down-Regulation, pubmed-meshheading:19273745-Endothelium, Vascular, pubmed-meshheading:19273745-Gene Transfer Techniques, pubmed-meshheading:19273745-Humans, pubmed-meshheading:19273745-Hyperglycemia, pubmed-meshheading:19273745-Lipoproteins, HDL, pubmed-meshheading:19273745-Male, pubmed-meshheading:19273745-NADPH Oxidase, pubmed-meshheading:19273745-Nitric Oxide Synthase Type III, pubmed-meshheading:19273745-Oxidative Stress, pubmed-meshheading:19273745-Rats, pubmed-meshheading:19273745-Rats, Sprague-Dawley, pubmed-meshheading:19273745-Receptor, Angiotensin, Type 1, pubmed-meshheading:19273745-Signal Transduction
pubmed:year
2009
pubmed:articleTitle
Vascular-protective effects of high-density lipoprotein include the downregulation of the angiotensin II type 1 receptor.
pubmed:affiliation
Department of Cardiology and Pneumology, Charité-University Medicine of Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't